ALCOHOL USE REDUCTION IN THE COURSE OF SMOKING CESSATION TREATMENT: A REVIEW Robert F. Leeman Stephanie S. O’Malley Yale University School of Medicine.

Slides:



Advertisements
Similar presentations
Jean-François ETTER Evelyne LASZLO Jean-Pierre ZELLWEGER Charles PERROT Thomas PERNEGER University of Geneva, Switzerland Smoking reduction with NRT: a.
Advertisements

1 Substance Misuse & Deployments Lt Col Jay Stone, Ph.D. Defense Centers of Excellence for Psychological Health & Traumatic Brain Injury 29 April 2009.
ABCs of Behavioral Support Jonathan Foulds PhD. Penn State – College of Medicine
Reading the Dental Literature
Smoking Cessation. Opportunity for Physicians 70 percent of smokers want to quit. Without assistance only 5 percent are able to quit. Most try to quit.
Treating Nicotine Dependence in Patients with Addictive Disorders Eric Heiligenstein, M.D. Director of Psychiatry University Health Services University.
Dennis M. Donovan, Ph.D., Michael P. Bogenschutz, M.D., Harold Perl, Ph.D., Alyssa Forcehimes, Ph.D., Bryon Adinoff, M.D., Raul Mandler, M.D., Neal Oden,
Journal Club Alcohol and Health: Current Evidence March-April 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009.
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May-June 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.
Journal Club Alcohol and Health: Current Evidence November-December 2005.
Journal Club Alcohol and Health: Current Evidence January-February 2006.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Journal Club Alcohol and Health: Current Evidence January-February 2005.
Psychiatric Comorbidity of Smoking and Nicotine Dependence: An Epidemiologic Perspective Naomi Breslau, Ph.D. Department of Epidemiology Michigan State.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2009.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
TREATING SPECIAL POPULATIONS. OVERVIEW Tobacco Treatment Smoking Outcomes Co-occurring Disorders Integration Tobacco Prevention.
Behavioral and Pharmacological Treatments for Smokers with Depression Richard A. Brown, Ph.D. Brown Medical School Butler Hospital, Providence, R.I.
Real-world effectiveness of nicotine replacement therapy in pregnancy Leonie S. Brose, PhD Andy McEwen, PhD & Robert West, PhD University College London.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Can undergoing an internet based ACT intervention change the impact of predictors thought to lead to Substance Use? Leonidou. G., Savvides. S., N. & Karekla.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
Introduction Smoking and Social Networks Joseph R. Pruis, Student Research Collaborator, Rosemary A. Jadack, PhD, RN, Professor Department Of Nursing,
CCTN September 6 th, Recent Scientific Publications from the Clinical Trials Network David Liu, M.D. (CTN-0029) Harold Perl, Ph.D. (CTN-0015) Paul.
Landmark Trials: Recommendations for Interpretation and Presentation Julianna Burzynski, PharmD, BCOP, BCPS Heme/Onc Clinical Pharmacy Specialist 11/29/07.
Raymond F. Anton, MD for The COMBINE Study Research Group
Co-Morbid Alcohol Use and Alcohol Use Disorders within Pathological Gamblers Jeremiah Weinstock, PhD Saint Louis University.
ABSTINENCE AND RELAPSE AMONG SMOKERS WHO USE VARENICLINE FOR QUITTING—A POOLED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Shade Agboola, Ann McNeill, Tim.
Laws/Policies ABSTRACT Problem: A challenge for tobacco control practitioners is getting smokers to quit using cessation methods. To increase the proportion.
Increasing Access to Pharmacotherapy Jonathan P. Winickoff, MD, MPH Associate Professor in Pediatrics Harvard Medical School April 26, 2013.
Nicotine dependence It’s in ICD 10! MRCPsych addiction psychiatry seminars March 2010.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Effects of a combination of varenicline and nicotine patch on post-quitting urges to smoke Katie Myers Smith BSc MSc CPsychol Research Fellow Wolfson Institute.
SMOKING in ADOLESCENTS with PSYCHIATRIC or ADDICTIVE DISORDERS.
1 Impact of Depression History on Tobacco Withdrawal and Relapse Among Female Smokers David W. Wetter, Ph.D. Department of Behavioral Science Funded by.
Module 3 Finding the Evidence: Pre-appraised Literature.
NRT & NRT+ Pilot Preliminary Results Gowri Shetty MS, MPH Gita Bewtra MPH.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2012.
Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.
Unit 11: Evaluating Epidemiologic Literature. Unit 11 Learning Objectives: 1. Recognize uniform guidelines used in preparing manuscripts for publication.
Types of Studies. Aim of epidemiological studies To determine distribution of disease To examine determinants of a disease To judge whether a given exposure.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Efficacy of Combination First Line Agents for Smoking Cessation Sneha Baxi, Pharm.D. Pharmacy Practice Resident University of Illinois at Chicago.
1 Access to and use of aids to smoking cessation in the UK Robert West University College London Austin, Texas February 2007.
Smoking in England Robert West Jamie Brown University College London 1.
Crystal Reinhart, PhD & Beth Welbes, MSPH Center for Prevention Research and Development, University of Illinois at Urbana-Champaign Social Norms Theory.
Specification 1. Primary Insomnia: Predisposing, precipitating and perpetuating factors Primary insomnia – No medical (or psychiatric or environmental)
Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.
1 Advising smokers on optimum pharmacotherapy for smoking cessation University College London April 2014 Robert West.
Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.
Clare Meernik, MPH 1 ; Anna McCullough, MSW, MSPH, CTTS 1 ; Leah Ranney, PhD 1 ; Barbara Walsh 2 ; Adam O. Goldstein, MD, MPH 1 Predictors of Quit for.
Meta-analysis of Effectiveness of First-Line Smoking Cessation Pharmacotherapies 6 Months After Quitting Medication Estimated OR (95% CI) Est. abstinence.
Smoking and smoking cessation in the real world
Development and Implementation of a Tobacco Cessation Toolkit
Robert West University College London London March 2008
Integrating Smoking Cessation with Substance Abuse Treatment
Get smoker to their baseline for their behavioral health condition and initiating abstinence from substances. Then assess whether, in the past year, was.
A systematic review of the relationship between substance abuse and psychotropic medication adherence: opportunities to improve outcomes for patients with.
Nicotine replacement therapy
ABCs of Behavioral Support
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Hilary Millar, Val Reilly, Liz McGovern
2009 Papers of Interest David Tinkelman.
Presentation transcript:

ALCOHOL USE REDUCTION IN THE COURSE OF SMOKING CESSATION TREATMENT: A REVIEW Robert F. Leeman Stephanie S. O’Malley Yale University School of Medicine

Abstract Given the well-established links between smoking and alcohol consumption, we began a literature review to assess the following: 1. the extent to which findings from clinical trials of nicotine replacement therapy (NRT) can be generalized to those with a current/past history of alcohol use disorders; 2. whether alcohol status affects smoking cessation outcome and 3. effects of smoking cessation on alcohol use. Just over half of the reports reviewed made mention of alcohol- related inclusion/exclusion criteria, with abuse being the most common criterion. Inclusion/exclusion criteria we described ambiguously in a high percentage of reports. Few studies reported any kind of findings concerning links between alcohol consumption and smoking cessation.

Introduction  There is strong evidence of co-morbidity between smoking and alcohol use  Evidence from animal and human research points to common genetic and biochemical underpinnings for tobacco and alcohol use/dependence  These findings have stimulated recent interest in implications for treatment

Co-Morbidity  44% of those who smoked in the last month reported at least one binge drinking episode during same time period 1  An estimated 74%-88% of those with substance abuse problems are also smokers 2  Approximately 35% of those with alcohol use disorders can also be classified as nicotine dependent 3  College student smokers are about 5 times more likely than non-smokers to be binge drinkers 4  Significant correlations have been found between reported urges to smoke and urges to drink during exposure to alcoholic beverages in the lab 5,6

Genetics/Biochemistry  There is a substantial genetic correlation between alcohol and nicotine use and dependence 7,8  There are several possible mechanisms for alcohol/tobacco links including evidence that smoking is associated with diminishing effects of alcohol 9 and an association between alcohol dependence and greater nicotine withdrawal 10  A number of candidate genes may underlie both alcohol and nicotine dependence (e.g., alpha 4 nicotinic receptor gene) 11  Several neurtransmitters and receptors are involved in both alcohol and nicotine effects including GABA 12, dopamine 13, serotonin 14 and endogenous opioids 15, these systems also likely influence risk of alcohol and nicotine dependence

Potential Treatment Implications  NRT is the primary pharmacotherapy for smoking cessation  Therefore, it is important to know whether NRT is efficacious for use in the large population of smokers who are heavy drinkers and those with past or current alcohol use disorders  Findings from NRT trials may not be generalizable to those with past/current alcohol use disorders due to exclusion criteria in place in clinical trials  If these findings are generalizable, they could help to determine what effect, if any, alcohol use status has on likelihood of smoking cessation  Findings from these trials could also help to address the issue of whether nicotine and alcohol use are substitutable or complementary substances

The Present Study Given the genetic/biochemical commonalities underlying smoking and drinking and the treatment implications of co-morbidity, we conducted a literature review to assess the following three issues: 1.The generalizability of findings in the NRT literature to heavy drinking smokers and those with current or past alcohol use disorders 2.The extent to which alcohol status affects smoking cessation outcome 3.The likelihood that smoking cessation will result in a reduction or increase in alcohol use

Method  We reviewed reports of nicotine replacement trials published in peer reviewed journals that were included in the recent Cochrane meta-analysis 16  We looked for presence/absence of alcohol-related inclusion/exclusion criteria, type of criteria and clarity with which criteria were described  In addition, we searched for information about the impact of alcohol status on smoking cessation outcome and for reported effects of smoking cessation on drinking behavior in the course of trials

Criteria for Inclusion in Review  Comparison between NRT and placebo or no treatment or between different doses of NRT  Post-treatment follow-up had to be at least 6 months  Cessation rates had to be reported for trials to be included  Only reports published in peer-reviewed journals were included  Our review covers the trials published between 1992 and March 2004 that were included in the Cochrane Report

Results  Of 69 reports published in peer reviewed journals during this time period that were included in the Cochrane meta-analysis, 68 were included in the present review (one report could not be located)  Including reports of trials making use of multiple treatment modalities, the most common modality was the patch (utilized in 45 trials), followed by the gum (15 trials), inhaler (10 trials), spray (7), tablet (2) and the lozenge (1)

Alcohol-Related Inclusion/Exclusion Criteria  Alcohol-related exclusion or inclusion criteria were reported in 35 of the 68 trials (51%)  Only one paper reported alcohol- related inclusion criteria, the rest reported exclusion criteria only

Types of Exclusion Criteria Alcohol abuse— past or present 20 (59%) Alcohol dependence only— past or present 10 (29%) Other 1 4 (12%) Type of Criteria 1 Alcohol problems of some kind (2), presence of an unstable alcohol disorder and alcohol misuse (1 each) Number of trials (percentage of the 34 w/exclusion criteria)

Clarity of Inclusion/Exclusion Criteria  In 60% of trials reporting alcohol-related inclusion/exclusion criteria, there was ambiguity 1 in description of criteria  In the 13 reports with clear exclusion criteria, time stipulations were as follows: no history whatsoever (2), the past year (5), the past six months (2), current/active disorder (4) 1 Ambiguity meaning lack of clarity with respect to the substances in question, the time frame being evaluated (e.g., lifetime, past six months) and/or the precise criteria being utilized

Effects of Alcohol Status on Smoking Cessation Two studies provided findings regarding effects of alcohol status on smoking cessation Croghan et al. (2003) reported no difference in smoking abstinence in a patch/spray trial based on lifetime alcohol dependence status Hughes et al. (2003) reported findings with the patch in a sample of smokers with a history of alcohol dependence that closely resembled results from a prior trial in a sample that was otherwise similar but without a dependence history

Effects of Smoking Cessation on Alcohol Use Only one of the studies reported findings concerning effects of smoking cessation on alcohol use: Hughes and colleagues (2003) found that in a sample of smokers with a past history of alcohol dependence, none of the participants relapsed to an alcohol use disorder while quitting smoking

Other Findings  Patterson et al. (2003) reported that alcohol use at baseline did not predict attendance at sessions for a patch/spray trial  Wisborg et al. (2000) reported that pregnant smokers who enrolled in their patch trial did not differ in level of alcohol use from those who expressed interest but did not enroll

Discussion  Slightly over half of the trials reviewed reported alcohol-related inclusion/exclusion criteria  Abuse was the most common exclusion criterion  Alcohol-related inclusion/exclusion criteria were described ambiguously in a high proportion of reports  Only 4 of the papers included in this review reported any data regarding associations between smoking and alcohol use  Given recent interest in links between smoking and alcohol use, this trend of infrequent reporting may have improved since the end of the most recent Cochrane meta-analysis of NRT upon which this review was based (i.e., April 2004 to the present)

Future Directions for Review  Papers published in 1991 and earlier that were included in the Cochrane meta-analyses will be added to the review  Papers published since the cutoff date for the Cochrane meta-analysis (March 2004) will be added as well  The review will also be expanded to include bupropion trials

Conclusions -Exclusion of individuals with a past or current history of an alcohol use disorder may limit the generalizability of results from NRT trials to this substantial population of smokers -Only 2 published papers included in this review examined effects of alcohol use status on smoking cessation -Based on this review, it is not possible to come to a conclusion about effects of smoking cessation on alcohol use -Future studies should incorporate measures of alcohol use at intake and during treatment in order to evaluate the generalizibility of results to those with varying alcohol use statuses and to improve our understanding of reciprocal relationships between alcohol use and smoking

References and Correspondence  References cited in the poster and papers included in the review are listed in the handout available from the presenter  Correspondence to: Robert F. Leeman, Ph.D. Yale University School of Medicine Department of Psychiatry 34 Park Street CMHC, Room S-213 New Haven, CT